


**REMARKS**

Currently claims 1 – 24 are pending. Applicants amend claims 1, 6, and 21 to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 25 – 30 are added herein. Claims 2, 7, 11 – 15, 19, and 23 – 24 are cancelled as being inappropriate to US practice. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. L. Lemanowicz', with a long, sweeping horizontal stroke at the end.

John L. Lemanowicz  
Attorney for Applicant  
Registration No. 37,380

Date: 10/11/04  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-8247  
Facsimile: 919-483-7988